TrialNature communications2024

The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial.

Qiao Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.